Nutrigenomics Market to Witness Impressive Growth, Reaching USD 6.66 Billion by 2030

July 02, 2024 10:43 PM AEST | By EIN Presswire
 Nutrigenomics Market to Witness Impressive Growth, Reaching USD 6.66 Billion by 2030
Image source: EIN Presswire

PORTLAND, OREGON, UNITED STATES, July 2, 2024 /EINPresswire.com/ -- The global nutrigenomics market size was valued at $435.7 million in 2022, and is projected to reach $2.1 billion by 2032, growing at a CAGR of 17.2% from 2023 to 2032.

Request Sample of the Report on Nutrigenomics Market Forecast 2032 – https://www.alliedmarketresearch.com/request-sample/A129082

Nutrigenomics studies the effect of nutrients on gene expression. In other words, nutrigenomics provides a genetic understanding of how common dietary components affect the balance between health and disease by altering the expression and/or structure of an individual’s genetic make-up.

Nutrigenomics Statistics:

The global nutrigenomics market is projected to reach $2.1 billion by 2032, growing at a Compound Annual Growth Rate (CAGR) of 17.2% from 2023 to 2032.
In North America, the demand for nutrigenomics is expected to expand rapidly due to growing health disorders.
The reagents and kits sub-segment is expected to grow at the highest CAGR of 17.5% during the forecast period from 2023 to 2032.
The obesity sub-segment accounted for the largest market share of 37.0% in 2022 and is expected to the highest grow at a CAGR of 18.1% during the forecast period.
The hospitals & clinics sub-segment of the global market accounted for the highest share of 46.8% in 2022 and is projected to continue to hold major market share by 2032.
The nutrigenomics market in the North America region accounted for the largest share of 43.9% in 2022 and is predicted to be dominant and grow at the highest CAGR of 18.0% during the forecast period.

Connect to our Analyst - https://www.alliedmarketresearch.com/connect-to-analyst/A129082

Product Type: Reagents and Kits Sub-segment to Flourish Immensely by 2032

The reagents and kits sub-segment accounted for the largest global nutrigenomics market share of 65.1% in 2022 and is expected to grow at the highest CAGR of 17.5% during the forecast period from 2023 to 2032. This is mainly due to the increase in number of chronic diseases and personalization of diet to prevent diseases due to unhealthy lifestyle and dietary change. Besides, the rising adoption of telehealth services that include pharmacy services, online medical visits, and memberships is driving the demand for reagents & kits.

Applications: Obesity Sub-segment to Dominate During the Forecast Period

The obesity sub-segment accounted for the largest market share of 37.0% in 2022 and is expected to the highest grow at a CAGR of 18.1% during the forecast period. This is mainly due to the increasing overweight population across the globe. The World Obesity Federation’s 2023 Atlas anticipates that more than 4 billion people, constituting 51% of the global population, will be either obese or overweight in the next 12 years.

Regional Analysis:

The nutrigenomics market in the North America region accounted for the largest share of 43.9% in 2022 and is predicted to be dominant and grow at the highest CAGR of 18.0% during the forecast period. This growth is mainly due to growing health disorders in the region. In addition, companies in North America are releasing genetic reports for their subscribers, which is contributing towards nutrigenomics research. Moreover, the presence of major nutrigenomics companies in the region is expected to generate opportunities in the nutrigenomics testing market in the coming years.

Market Segmentation:

By Product Type:

Reagents and Kits
Services

By Applications:

Diabetes
Cardiovascular Diseases
Cancer Research
Obesity

By End User:

Online Platforms
Hospitals and Clinics
Others

By Region:

North America (U.S., Canada, Mexico)
Europe (Germany, UK, France, Spain, Italy, Rest of Europe)
Asia-Pacific (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
LAMEA (Brazil, UAE, Saudi Arabia, South Africa, Rest of LAMEA)

Key Player Analysis:

Nutrigenomix Inc.
Metagenics, Inc.
The Gene Box
DNA Life
GX Sciences Inc.
Genova Diagnostics
Holistic Health
Cura Integrative Medicine
Xcode Life

For Procurement Information - https://www.alliedmarketresearch.com/purchase-enquiry/A129082

About Allied Market Research:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

David Correa
Allied Market Research
+1 800-792-5285
email us here
Visit us on social media:
Facebook
X


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.